Megan Hollasch

Articles

Tucatinib/Trastuzumab Combination Finds a Role in HER2+ mCRC

February 2nd 2023

John H. Strickler, MD, highlights key findings from the MOUNTAINEER trial and addresses the possibility of moving the combination up to the first line setting.

Pirtobrutinib’s Approval Addresses Unmet Need in MCL Treatment Paradigm

January 31st 2023

Michael L. Wang, MD, discusses the efficacy of the noncovalent BTK inhibitor pirtobrutinib, as well as safety data from the phase 1/2 BRUIN trial in mantle cell lymphoma.

Investigators Unpack Potential Role of Nab-Sirolimus for Solid Tumors With TSC1/2 Mutations

January 27th 2023

Brian Schulte, MD, discusses the relevance of these mutations and an actively enrolling phase 2 PRECISION-1 basket trial investigating the efficacy of nab-sirolimus in solid tumors.

Promising Efficacy and Safety Demonstrated With Envafolimab, Lenvatinib, and TACE in Unresectable HCC

January 20th 2023

Findings from the phase 2 CISLC-12 study show favorable safety and efficacy signals for patients with unresectable hepatocellular carcinoma treated with the combination of envafolimab, lenvatinib, and transarterial chemoembolization.

The Keys to Speaking Media Language Unlock Potential for Institutions and Investigators

January 13th 2023

Joyce Ohm, PhD, details the significance of Twitter’s platform as she’s seen it grow over the years, and Peter Soscia explains the behind-the-scenes of managing communications.

Unique Properties of Uproleselan Demonstrates Promise in AML

January 9th 2023

Eunice Wang, MD, highlights the mechanism of action of E-selectin inhibitors and speaks on the safety profile and efficacy of uproleselan in patients with acute myeloid leukemia.

Mirvetuximab Soravtansine Accelerated Approval Helps Fill Unmet Need in Platinum Resistant Ovarian Cancer

January 3rd 2023

Ursula A. Matulonis, MD, discusses the novelty of mirvetuximab soravtansine in platinum-resistant ovarian cancer, and how it will expand options for a traditionally difficult-to-treat population.

Randall Highlights Advances in Reconstruction Techniques for Patients With Bone Sarcomas

December 25th 2022

Robert Lawrence Randall, MD, FACS, discussed the role of biological reconstructions as well as factors that determine whether a patient would benefit more from the reconstructions or traditional prosthetics known as endoprosthetics.

In-House Next-Generation Sequencing Improves Turnaround Time in NSCLC

December 22nd 2022

Lauren Ritterhouse, MD, PhD, discusses next-generation sequencing testing platforms and the importance of establishing processes for tissue collection in non–small cell lung cancer.

Adagrasib Provides New Option for Patients with KRAS G12C–Mutant NSCLC

December 22nd 2022

The FDA’s accelerated approval of adagrasib for adult patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer who have received at least 1 prior systemic therapy has provided a second KRAS G12C inhibitor option for patients.

Radiation Therapy Plus Surgery May Improve Local Control in Localized Pelvic Ewing Sarcoma

December 22nd 2022

R. Lor Randall, MD, FACS, discusses the significance of addition of surgery to radiation therapy led to improved local control compared with radiation therapy alone in patients with localized pelvic Ewing Sarcoma.

Bioequivalence Study Results Showcase Reduced Variability With Dasatinib ASD Formulation

December 16th 2022

Leif Stenke, MD, PhD, discusses the role XS004 may have in future clinical development in chronic myeloid leukemia.

Emerging Agents Signal Promising Opportunities to Expand Treatment Options for CLL

December 15th 2022

Anthony Mato, MD, MSCE, discusses the relapsed refractory setting compared with the frontline setting and promising agents such as pirtobrutinib and zanubrutinib.

Updated EMERALD Data Support Oral SERD Elacestrant As a Potential Option for Metastatic Hormone Receptor–Positive Breast Cancer

December 14th 2022

The oral selective estrogen receptor degrader elacestrant has shown promise over standard second-line treatment, such as fulvestrant, for patients with metastatic hormone receptor–positive breast cancer.

Cilta-Cel Shows Efficacy and Tolerability in Multiple Myeloma, Potentially Filling Unmet Need in Early-Line Therapy

December 13th 2022

The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.

Zanubrutinib Demonstrates Efficacy and Safety in Acalabrutinib-Intolerant Patients with B-Cell Malignancies

December 12th 2022

Updated results from the ongoing phase 2 BGB-3111-215 trial showed that zanubrutinib provided clinically meaningful benefit to a large majority of efficacy-evaluable patients with B-cell malignancies who were intolerant to acalabrutinib.

Trastuzumab Deruxtecan With or Without Pertuzumab Demonstrates Early Safety and Efficacy Signals in HER2+ MBC

December 9th 2022

Trastuzumab deruxtecan, both as monotherapy and in combination with pertuzumab, displayed encouraging efficacy with no new safety signals among patients with HER2-positive metastatic breast cancer, according to findings from the dose expansion part of the phase 1b/2 DESTINY-Breast07 trial.

The State of Biosimilars: Obstacles and Barriers to Use in 2022

December 7th 2022

With patents expiring on some of the revolutionary agents in cancer treatment, the emergence of biosimilars as a lower-cost option has seen exponential growth.

Tremelimumab Plus Durvalumab Receives Go-ahead for Treatment of HCC

November 30th 2022

Ghassan K. Abou-Alfa, MD, discusses the administration of tremelimumab plus durvalumab in hepatocellular carcinoma and where the combination will fit in the treatment paradigm.

Expanding Treatment Options Elevate Outcomes for Patients With Myelofibrosis

November 28th 2022

John Mascarenhas, MD, discusses the shifts from monotherapy to combination therapies in the evolving field of myelofibrosis care.